Effect of New Therapy Lasts Longer for Patients with Neovascular Age-Related Macular Degeneration

Faricimab every 16 weeks offers similar benefits as aflibercept every eight weeks

21-EYE- 2468445- CQD – Faricimab in Neovascular

A new type of therapy offers patients with neovascular age-related macular degeneration longer lasting results than current therapies. This is welcome news for a population of patients for whom frequency of treatment can be inconvenient if not an outright barrier.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In a phase 3 clinical trial, researchers compared aflibercept, the current standard of care, with new drug faricimab. The study found that faricimab offered similar benefits at 16-week intervals as aflibercept given at eight-week intervals.

“There is a lot of unmet need with regard to therapies for age-related macular degeneration,” says retina specialist Rishi P. Singh, MD, of Cleveland Clinic’s Cole Eye Institute. “Treatments are high frequency, and patients continue to lose vision, despite having frequent injections. I think ophthalmologists will see faricimab as a potential new market leader, with superior durability.”

Dr. Singh presented findings from the phase 3 study at the American Academy of Ophthalmology 2021 meeting. He said he hopes faricimab will receive FDA approval early next year, with the drug becoming available for clinical use by the end of 2022.

Combining anti-VEGF with anti-Ang-2

Faricimab uses a new pathway to treat age-related macular degeneration. Current medications work by blocking vascular endothelial growth factor (VEGF). Faricimab combines the anti-VEGF method of action with an additional molecule that blocks angiopoietin-2 (Ang-2), a different growth factor that drives vascular destabilization.

“It’s an anti-Ang-2 drug and an anti-VEGF drug combined on a single platform,” says Dr. Singh. “I think the dual method of action makes sense because the anti-VEGF therapy alone seems insufficient for many patients. This gives us an alternative to that pathway.”


More durability can improve quality of life

Under the current standard of care, most patients need to receive injections directly into their eyes every eight to nine weeks in order to maintain results and prevent vision loss.

In addition to the hardship of frequent injections, patients lose vision quickly if they miss treatments. An earlier study by Dr. Singh’s team found notable vision loss in patients who missed treatments as a result of the COVID-19 pandemic.

“We need more durable treatments,” says Dr. Singh. “Obviously, if you have to come in for injections once a month or every two months versus every four months or every six months, it can make a huge difference in your quality of life.”

Superior drying effect, no significant side effects

Faricimab also had a superior drying effect compared to aflibercept, reducing retinal fluid, especially in patients with diabetic macular edema, Dr. Singh noted.

The multi-institute study involved 1,329 patients at sites around the world. After 48 weeks, 80% of the faricimab patients were at dosing intervals greater than 12 weeks, and 45% were at 16-week intervals.


Faricimab had no significant side effects compared to the standard of care.

Related Articles

OCT scan showing dry AMD
Autoimmune Disease Linked With Higher Risk of Macular Degeneration

Early data shows risk is 73% higher in patients with lupus, 40% higher in patients with rheumatoid arthritis

Could Inflammation Be the Reason Why Human Retinas Don’t Regenerate?

Researchers to study retinal regeneration in zebrafish with new grant from National Eye Institute

Don’t Believe Everything Chatbots Say About Ophthalmic Research

30% of references generated by ChatGPT don’t exist, according to one study

22-EYE-3066210 CQD-Losartan for corneal fibrosis-Wilson-hero
Hypertension Drug Losartan Reverses Scarring and Restores Vision After Cornea Damage

Studies indicate dramatic results when used topically with or without corticosteroids

22-EYE-3141638 CQD-EYP-1901 with vorolanib for maintenance of nAMD
DAVIO Trial Results: Vorolanib Injection Reduces Treatment Burden for Patients with nAMD

53% of participants didn’t need anti-VEGF for six months or longer

22-EYE-3049477 New findings in retinal regeneration-Perkins-650×450-4
Restoring the Retina: How to Regenerate Photoreceptors in Inherited Retinal Dystrophy

Notch pathway inhibition preserves retinal neurons and promotes regrowth in zebrafish